Alnylam Pharmaceuticals
🇬🇧United Kingdom
- Country
- 🇬🇧United Kingdom
- Ownership
- -
- Established
- 2002-01-01
- Employees
- -
- Market Cap
- $35.9B
- Website
- http://www.alnylam.com/
A Study of an Investigational Drug, Cemdisiran (ALN-CC5), in Patients With Atypical Hemolytic Uremic Syndrome
- First Posted Date
- 2017-10-06
- Last Posted Date
- 2018-10-01
- Lead Sponsor
- Alnylam Pharmaceuticals
- Registration Number
- NCT03303313
- Locations
- 🇸🇪
Clinical Trial Site, Örebro, Sweden
A Study to Evaluate Long-term Safety and Clinical Activity of Givosiran (ALN-AS1) in Patient With Acute Intermittent Porphyria (AIP)
- First Posted Date
- 2016-10-31
- Last Posted Date
- 2024-03-12
- Lead Sponsor
- Alnylam Pharmaceuticals
- Target Recruit Count
- 16
- Registration Number
- NCT02949830
- Locations
- 🇬🇧
Clinical Trial Site, London, United Kingdom
Expanded Access Protocol of Patisiran for Patients With Hereditary ATTR Amyloidosis (hATTR)
- First Posted Date
- 2016-10-20
- Last Posted Date
- 2024-05-20
- Lead Sponsor
- Alnylam Pharmaceuticals
- Registration Number
- NCT02939820
A Study of ALN-HBV in Healthy Adult Volunteers and Non-cirrhotic Patients With Chronic Hepatitis B Virus (HBV) Infection
Phase 1
Terminated
- Conditions
- Interventions
- First Posted Date
- 2016-07-07
- Last Posted Date
- 2018-09-24
- Lead Sponsor
- Alnylam Pharmaceuticals
- Target Recruit Count
- 24
- Registration Number
- NCT02826018
- Locations
- 🇬🇧
Clinical Trial Site, London, United Kingdom
A Safety and Tolerability Study of an Investigational Drug, ALN-TTRSC02, in Healthy Subjects
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2016-06-14
- Last Posted Date
- 2018-09-21
- Lead Sponsor
- Alnylam Pharmaceuticals
- Target Recruit Count
- 80
- Registration Number
- NCT02797847
- Locations
- 🇬🇧
Clinical Trial Site, London, United Kingdom
Study of Lumasiran in Healthy Adults and Patients With Primary Hyperoxaluria Type 1
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2016-03-11
- Last Posted Date
- 2020-01-30
- Lead Sponsor
- Alnylam Pharmaceuticals
- Target Recruit Count
- 52
- Registration Number
- NCT02706886
- Locations
- 🇬🇧
Clinical Trial Site, London, United Kingdom
The Study of an Investigational Drug, Revusiran (ALN-TTRSC), for the Treatment of Transthyretin (TTR)-Mediated Amyloidosis in Patients Whose Disease Has Continued to Worsen Following Liver Transplant
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2015-11-04
- Last Posted Date
- 2019-03-28
- Lead Sponsor
- Alnylam Pharmaceuticals
- Target Recruit Count
- 12
- Registration Number
- NCT02595983
- Locations
- 🇬🇧
Clinical Trial SIte, London, United Kingdom
🇸🇪Clinical Trial Site, Umea, Sweden
The Study of an Investigational Drug, Patisiran (ALN-TTR02), for the Treatment of Transthyretin (TTR)-Mediated Amyloidosis in Participants Who Have Already Been Treated With ALN-TTR02 (Patisiran)
- First Posted Date
- 2015-07-29
- Last Posted Date
- 2023-12-06
- Lead Sponsor
- Alnylam Pharmaceuticals
- Target Recruit Count
- 211
- Registration Number
- NCT02510261
- Locations
- 🇬🇧
Clinical Trial Site, London, United Kingdom
A Study of an Investigational Drug, ALN-AAT, in Healthy Adult Subjects and Patients With ZZ Type Alpha-1 Antitrypsin Deficiency Liver Disease
Phase 1
Terminated
- Conditions
- Interventions
- First Posted Date
- 2015-07-21
- Last Posted Date
- 2019-01-07
- Lead Sponsor
- Alnylam Pharmaceuticals
- Target Recruit Count
- 26
- Registration Number
- NCT02503683
- Locations
- 🇬🇧
Richmond Pharmacology, Ltd., London, United Kingdom
A Phase 1 Study of Givosiran (ALN-AS1) in Patients With Acute Intermittent Porphyria (AIP)
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2015-05-22
- Last Posted Date
- 2018-06-14
- Lead Sponsor
- Alnylam Pharmaceuticals
- Target Recruit Count
- 40
- Registration Number
- NCT02452372
- Locations
- 🇬🇧
Clinical Trial Site, London, United Kingdom
© Copyright 2024. All Rights Reserved by MedPath